Nanotechnology Archives

News and Trends 20 Jul 2017

Sanofi Offers up to €2.4Bn to Belgian Biotech to Develop Nanobodies

Ablynx and Sanofi have entered a research collaboration and exclusive licensing agreement for up to eight nanobody candidates for immune and inflammatory disease. Ablynx, based in Belgium, develops nanobodies, single-domain antibodies inspired on those of camels and llamas that have the advantage of being much smaller than standard antibodies. This technology has caught the attention of Sanofi, […]

July 20, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 23 May 2017

Merck to Pay Ablynx €15M for Getting a Second Nanobody ready for the Clinic

Ablynx is receiving its first milestone payment from a deal with Merck for the development of first-in-class treatments for osteoarthritis. Belgium-based Ablynx develops nanobodies, molecules with the same properties as antibodies but with the advantage of being much smaller. This technology has attracted top pharma partners like AbbVie, MSD, Boehringer Ingelheim and Novartis. Now, the third […]

May 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 30 Mar 2017

Merck Outsources the Development of its Nanobody for Psoriasis

Merck has signed a new agreement with Avillion for its nanobody against psoriasis. Avillion will advance the nanobody from Phase II through Phase III. As part of several partnerships between Merck and the unbeaten nanobody biotech Ablynx, Merck recently cleared Phase Ib with its llama-inspired nanobody targeting the cytokines IL-17 A/F for the treatment of plaque psoriasis. The antibody […]

March 30, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 12 Jan 2017

An Antibody to reduce Hospitalizations of Children starts Phase IIb trials

Ablynx has treated its first patient in a new trial targeting RSV infections, the main cause of children hospitalizations. Ablynx, one of the few European biotechs that made it into JP Morgan this year, develops nanobodies derived from llamas. The Belgian company announced yesterday that its candidate ALX-0171 has entered testing in Phase IIb as a treatment […]

January 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Sep 2016

This company just turned the lights ON for NanoMed Bioplastic

Bio-ON just patented the first application of bioplastic in nanomedicine with a diagnostic tool for cancer that will grant it access to a whole new market previously inaccessible to this industry. Italy-based Bio-ON is trying to change the world by producing alternative sustainable chemicals and bioplastic materials with industrial applications. Their newest product, minerv BIOMEDS, will be used […]

September 20, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

dresden spermbot sperm nanotechnology biotech IFW

News and Trends 12 May 2016

Sperm Cells Enlisted as Nanobot Delivery Guys

Reserchears at IFW Dresden were trying to create a nanorobot for drug delivery and even gene manipulation. They ended up using one of the motors created by nature – the flagella of sperm cells. Drug delivery is a key part in the development of new drugs, and an active field of research with academy-industry partnerships. Examples of ideas […]

May 12, 2016 - 3 minutesmins - By Denise Neves Gameiro

ablynx llama antigody nanobody rsv infant

News and Trends 3 May 2016

Llama Antibody Inhalation gets Positive Results for Respiratory Virus

Ablynx has gotten positive results for its candidate (ALX-0171) in Phase I/IIa trial for infants infected with a life-threatening virus – respiratory syncytial virus (RSV). Located near Ghent (Belgium), Ablynx is making advances in its Nanobody platform, based on the shorter monoclonal antibodies of llamas. Due to their small size, these Nanobodies can be used in a […]

May 3, 2016 - 2 minutesmins - By Denise Neves Gameiro

biomoti oncojan physiomics virtual tumor

News and Trends 1 Apr 2016

When Nanoparticles meet Virtual Tumours to build Oncology Platform

BioMoti is enhancing cancer treatments via drug delivery innovation and it was one of the companies we visited during Labiotech Tour UK. Its Oncojan platform has caught the eye of Physiomics, a computational system biology Biotech listed on the London Stock Exchange. Oxford-based Physiomics develops computational models of cancer, allowing to simulate the effect of […]

April 1, 2016 - 3 minutesmins - By Denise Neves Gameiro

bionic heart patch university tel aviv tau biomaterial nanoelectronics tissue engineering myocardial infarction heart attack nature materials

News and Trends 16 Mar 2016

‘Cyborg’ Heart Patch to Revolutionize Treatment of Heart Attacks

Researchers from Tel Aviv University (Israel) have managed to engineer a Nanotech ‘heart patch’ which could enable remote monitoring and regulation of a patient’s heart – bionic! MedTech continues to blur the boundary between man and machine. A new project combines organic, living tissue and a complex nanoelectronic system to create a bionic heart patch that could help […]

March 16, 2016 - 3 minutesmins - By Denise Neves Gameiro

nanobiotix private placement €21M nanoxray sarcoma liver head neck prostate cancer nbtxr3 nanomedicine radiotherapy localized

News and Trends 15 Mar 2016

French Nanomedicine Biotech Gets €21M to Kill Cancer with ‘Beam Rays’

Nanobiotix (France) has had a successful private placement in, raising €21.3M to advance the clinical development of its localised radiotherapy for Cancer. Located in Paris’ superbiocluster, Nanobiotix wants to change the way cancer is treated – but in a different way from most Biotech strategies. It is developing NanoXRay, a paradigm-shifting nanotechnology for localised radiotherapy. Nanobiotix has […]

March 15, 2016 - 2 minutesmins - By Denise Neves Gameiro

nanomedicine nanoxray nanobiotix prostatecancer trials

News and Trends 4 Jan 2016

French Nano-Xrays to Kill Prostate Cancer in Phase I/II Trial

A Parisian Nanomedicine biotech is using it’s proprietary NanoXray technology to enhance radiotherapy. Now a candidate to treat Prostate cancer has received FDA approval for a phase I/II trial in the US. Nanobiotix is seeking to develop NBTXR3 for patients with intermediate and high-risk prostate cancer, with the aim of providing effective tumor destruction and […]

January 4, 2016 - 3 minutesmins - By Dani Bancroft

ablynx antibodies rsv infection nanobody llama

News and Trends 18 Dec 2015

64 Million RSV Infections Per Year: Perhaps Alpaca Nanobodies Will Save Infant Lives

Ablynx, the Alpaca Nanobody Biotech from Belgium, has completed target enrollment of the first-in-infant Phase I/IIa study with its anti-Respiratory Syncytial virus, which is linked to 3,000-8,500 infant deaths each year. ALX-0171 is a wholly-owned Nanobody drug candidate administered through inhalation (nebulisation), for the treatment of respiratory syncytial virus (RSV) infection in infants. The candidate […]

December 18, 2015 - 3 minutesmins - By Dani Bancroft

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us